DGAP-News

CORRECTING and REPLACING -- Novavax to Present RSV Vaccine Preclinical Results at ICAAC

DGAP-News: Novavax, Inc.
CORRECTING and REPLACING -- Novavax to Present RSV Vaccine Preclinical
Results at ICAAC

04.09.2014 / 00:25

---------------------------------------------------------------------

GAITHERSBURG, Md., 2014-09-04 00:25 CEST (GLOBE NEWSWIRE) --
In a release issued earlier today by Novavax, Inc.(Nasdaq:NVAX), the headline
read 'Novavax to Present RSV Vaccine Clinical and Preclinical Results at
ICAAC'. The headline should now read 'Novavax to Present RSV Vaccine
Preclinical Results at ICAAC'.

The corrected release follows:

Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biopharmaceutical company focused
on the discovery, development and commercialization of recombinant nanoparticle
vaccines and adjuvants, announced today that it will present data from recent
preclinical studies of its respiratory syncytial virus F-protein nanoparticle
vaccine candidate (RSV F Nanoparticle Vaccine) at the 54th Interscience
Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Washington,
D.C., September 5-9, 2014 at the Walter E. Washington Convention Center.

The presentation numbers, titles, dates and times are listed below:

-- Poster Session 024: I-314b. 'Development and Characterization of
Recombinant RSV F Nanoparticle Vaccine Induced Monoclonal Antibody'
[Exhibit Hall B, Saturday, September 6, 2014 from 12:00 to 2:00 pm]
-- Slide Session Number 077: I-649. 'Immunization of Pregnant Baboons with the
RSV F Nanoparticle Vaccine Protects Infant Baboons Challenged with
Respiratory Syncytial Virus in a Comparable Manner to Infants Prophylaxed
with Palivizumab'
[Meeting Room 209A, Sunday, September 7, 2014 from 8:45 to 9:00 am]

About Novavax

Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage biopharmaceutical company
creating vaccines and vaccine adjuvants to address a broad range of infectious
diseases worldwide. Using innovative proprietary recombinant nanoparticle
vaccine technology, the company produces vaccine candidates to efficiently and
effectively respond to both known and newly emergent diseases.

CONTACT: Barclay A. PhillipsSVP, Chief Financial Officer and TreasurerNovavax,
Inc.240-268-2000
News Source: NASDAQ OMX



---------------------------------------------------------------------

04.09.2014 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------


Language: English
Company: Novavax, Inc.


United States
ISIN: US6700021040


End of News DGAP News-Service
---------------------------------------------------------------------
285491 04.09.2014